Tetraspanins stimulate protein synthesis in myeloma cell lines

Victoria Zismanov1, Liat Drucker, Oshrat Attar-Schneider

  • 1Oncogenetic Laboratory, Meir Medical Center, Kfar Saba, Israel.

Insights

Overexpressing tetraspanins in multiple myeloma (MM) cells increases protein synthesis, leading to cell death. This suggests targeting excessive protein translation could be a novel therapeutic strategy for MM.

Area of Science:

  • Cancer Biology
  • Cellular Metabolism
  • Molecular Oncology

Background:

  • Multiple myeloma (MM) cells exhibit intensive protein synthesis, a unique characteristic.
  • Tetraspanin (CD81, CD82) overexpression in MM cell lines previously linked to UPR and autophagic death.
  • Protein homeostasis is critical in MM due to high protein production and microenvironmental interactions.

Purpose of the Study:

  • To investigate the role of protein synthesis in tetraspanin-induced multiple myeloma cell death.
  • To explore the mechanisms by which tetraspanins influence protein translation and cell viability in MM.
  • To identify potential therapeutic targets related to protein synthesis in multiple myeloma.

Main Methods:

  • Transfection of MM cell lines (RPMI-8226, CAG) with CD81/CD82.
  • Measurement of steady-state protein levels and immunoglobulin production.
  • Analysis of cell morphology, phospho-rpS6, phospho-AMPK, and p38 involvement.
  • Microarray analysis to identify activated signaling cascades and ribosome biogenesis pathways.

Main Results:

  • Tetraspanin overexpression led to elevated protein synthesis, independent of mTOR attenuation.
  • Increased phospho-rpS6 and decreased phospho-AMPK levels indicated enhanced translation.
  • p38 activation was involved in tetraspanin-induced translation and cell death.
  • Microarray data revealed activation of protein synthesis and ribosome biogenesis pathways.

Conclusions:

  • Excessive protein translation, induced by tetraspanins, is detrimental to multiple myeloma cells.
  • Targeting elevated protein synthesis represents a potential novel therapeutic strategy for MM.
  • Manipulating protein translation could exploit a vulnerability in MM cells, offering a new therapeutic platform.

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...